



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

02 June 2015

[\[Click on blue hyperlink for further information\]](#)

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Please be advised that you **must contact the Research Grants Management Office (RGMO) at least 60 days before the submission date**, Mr Eugene Baugaard (eugeneb@sun.ac.za), or as soon as you commit to apply for an NIH grant and that the grant is submitted institutionally.

Important notices

- [Clarifying Publication Reporting Instructions for Research Performance Progress Reports \(RPPR\) and Renewal Applications \(NOT-OD-15-091\)](#)
- [Notice of Clarification on Research Objectives in RFA-AI-15-020 "NIH-PEPFAR Collaboration on Implementation Science for HIV: Towards an AIDS-free Generation \(R01\)" \(NOT-AI-15-034\)](#)

1. Title: Mucosal Immunology Studies Team (MIST)

Letter of Intent due date: September 20, 2015

Hyperlink: [\(RFA-AI-15-023\)](#)

Type: U01

Application Due Date: October 20, 2015, by 5:00 PM local time of applicant organization.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from institutions/organizations to participate in a cooperative research group, the Mucosal Immunology Studies Team (MIST), focusing on immune defense mechanisms and immune regulation at mucosal surfaces of the respiratory, gastrointestinal and urogenital tracts. The purpose of this funding opportunity is to break new ground in the understanding of basic mucosal immune defense mechanisms by introducing new ideas, approaches and technologies that address the difficult questions remaining in mucosal immunology.

Budget: For this funding opportunity, budgets may be requested up to \$850,000 direct costs per year which includes a limit on the budget for the Infrastructure and Opportunity Fund of \$500,000 direct costs per year, and a limit on the U01 research project of \$350,000 direct costs per year. Application budgets need to reflect the actual needs of the proposed project. Consortium F & A is not included in the direct cost limitation. The total project period may not exceed 5 years.

2. Title: Harnessing Genome Editing Technologies to Functionally Validate Genetic Variants in Substance Use Disorders

Letter of Intent due date: July 25, 2015

Hyperlink: [\(RFA-DA-16-004\)](#)

Type: R21/R33

Application Due Date: August 25, 2015, by 5:00 PM local time of applicant organization.

Purpose: The purpose of this initiative is to harness genome or epigenome editing technologies to functionally validate and characterize genetic or epigenetic variants involved in substance use disorders. The purpose is also that the genetic resources generated will be made broadly available to the scientific community to probe more deeply into the neurobiological mechanisms involved in the function of a variant, gene, or pathway and provide critical foundational knowledge for the development of future prevention, diagnostic, and therapeutic strategies.

Budget: Application budgets may not exceed \$125,000 per year in direct costs for the R21 phase. Applications may not exceed \$250,000 per year in direct costs for the R33 phase. The R21 phase may not exceed two years, while the R33 phase may not exceed 3 years. The total project period may not exceed 5 years.

3. Title: Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation

Letter of Intent due date: N/A

Hyperlink: [\(PA-15-268\)](#)

Type: R34

Application Due Date: Standard Aids dates apply, by 5:00 PM local time of applicant organization 7 Jan, 7 May, 7 Sep

Purpose: This FOA provides resources to support (a) pilot or feasibility studies of new or adapted interventions to prevent HIV infection among populations where substance use may be a contributing factor; (b) pilot or feasibility studies of new or adapted interventions to improve the care of HIV infection among populations where substance use is prevalent, including interventions that integrate treatment for substance use disorders and HIV infection; or (c) pilot or feasibility studies to increase the scale, uptake, delivery, and/or quality of HIV prevention or care interventions with established evidence of efficacy. Both primary and secondary prevention will be supported. The full range of substance use will be considered including problematic episodic use and substance use disorders, as well as a full range of substances and modes of administration. The most important consideration is that substance use may affect transmission directly as in the case of injection or may affect transmission risk behavior. Domestic and overseas populations will be considered, with particular attention to populations with disproportionate burden of HIV infection and those where HIV infection and/or drug use are emergent.

Budget: Direct costs are limited to \$450,000 over a three-year period, with no more than \$225,000 direct costs allowed in any single year. The maximum period is 3 years.

4. Title: Fast-Track Development of Medications to Treat Cannabis Use Disorders

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** [\(PAR-15-267\)](#) **Type** UG3/UH3

Application Due Date: July 28, 2015; March 28, 2016; July 28, 2016; March 28, 2017; July 28, 2017; March 28, 2018, by 5:00 PM local time of applicant organization. – Aids Applications: September 7, 2015; May 7, 2016; September 7, 2016; May 7, 2017; September 7, 2017; May 7, 2018, by 5:00 PM local time of applicant organization

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the discovery and development of medications to treat Cannabis Use Disorders (CUDs) using the UG3/UH3 mechanism. The objective is to advance medications toward the ultimate goal of obtaining FDA approval. Advances in understanding the cannabinoid systems and the effects of marijuana on the brain, coupled with the availability of both novel and marketed medications that may be efficacious to treat these disorders, offer unprecedented opportunities to develop safe and effective pharmacotherapies for CUDs.

The compounds to be evaluated can be small molecules or biologics. They can be tested in pre-clinical models and/or for the clinical manifestations of CUDs or their consequences such as withdrawal, craving, or cannabis use relapse. Applications may focus on the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications that hold promise for the treatment of CUDs.

The UG3/UH3 Phase Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases.

Through this FOA, NIDA seeks to fast-track the discovery and development of pharmacotherapies for CUDs and to advance them in the FDA's drug development approval pipeline.

Budget: Application budgets are limited to \$1,000,000 direct costs and need to reflect the actual needs of the proposed project. The project period is limited to 2 years for the UG3 phase and 3 years for the UH3 phase.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

UH2/UH3 - Phase Innovation Awards Cooperative Agreement: Exploratory/Developmental Cooperative Agreement Phase I and II. To support the development of new research activities in categorical program areas (Support generally is restricted in level of support and in time.) The UH3 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the UH2 mechanism. Although only UH2 awardees are generally eligible to apply for UH3 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under UH2.

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R25 – NIH Education Projects: used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

R34 – Research Projects Planning Grant: To provide support for the initial development of a clinical trial or research project, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design or experimental research designs and other essential elements of the study or project, such as the protocol, recruitment strategies, procedure manuals and collection of feasibility data.

G11 Extramural Associate Research Development Award (EARDA) : G11 Extramural Associate Research Development Award (EARDA) To provide funds to institutions eligible to participate in the NIH Extramural Associates Program for establishing or enhancing an office of sponsored research and for other research infrastructure needs.

Complete [Glossary and acronym list of NIH Terms](#)



Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus. • Enquiries: [Dr Christa de Vries](#) • Tel: 9838 • Email: cdevries@sun.ac.za